A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs SAR 440340 (Primary) ; SAR 440340 (Primary)
- Indications Inflammation
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 06 Nov 2017 Status changed from active, no longer recruiting to completed.
- 19 May 2017 Planned End Date changed from 1 Feb 2017 to 1 Sep 2017.
- 19 May 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Sep 2017.